CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
November 9, 2026
CMS has finalized the GLOBE Model drug pricing rule. It is a mandatory Medicare payment model that tests whether benchmarking Part B drug inflation rebates against international prices can reduce spending for Original Medicare while preserving quality of care. The rule was published in the Federal Register on 2 October 2026 (FR Doc. 2026-20281, CMS-5545-F) and takes effect on 30 November 2026.
How GLOBE Model drug pricing sets the benchmark
The model builds on the Medicare Part B Drug Inflation Rebate Program, created by the Inflation Reduction Act. That program requires manufacturers to pay a rebate when they raise prices faster than inflation. GLOBE keeps that rebate and adds a second test. For covered drugs, a manufacturer owes a GLOBE rebate when the Part B payment amount exceeds an international benchmark. The GLOBE rebate cannot be lower than any inflation rebate already owed.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.